Chimerix (NASDAQ:CMRX) Posts Earnings Results, Misses Estimates By $0.04 EPS

Chimerix (NASDAQ:CMRX) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04), Zacks reports. Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 39.62%. During the same quarter last year, the firm posted ($0.24) earnings per share.

Chimerix Stock Performance

Shares of CMRX opened at $0.95 on Friday. The stock has a fifty day moving average price of $1.04 and a two-hundred day moving average price of $1.00. Chimerix has a 52-week low of $0.88 and a 52-week high of $1.57.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on CMRX shares. StockNews.com cut shares of Chimerix from a “hold” rating to a “sell” rating in a research note on Friday. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Chimerix in a research report on Friday, March 1st. Finally, Wedbush restated an “outperform” rating and issued a $6.00 price target on shares of Chimerix in a research report on Monday, February 12th.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.